Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Modena – page 12

387 clinical trials in Modena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Modena at a glance
387
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

387 trials in Modena

Open in trial search

Plasma cell myeloma

Recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

End stage renal disease

Recruiting

Study on XyloCore and Drug Combination for Patients with End-Stage Kidney Disease Undergoing Peritoneal Dialysis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Iperboreal Pharma S.r.l.

Chronic lymphocytic leukaemia

Recruiting

Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Small intestine adenocarcinoma

Recruiting

Study on the Effectiveness of FOLFIRINOX and FOLFOX for Patients with Advanced Small Bowel Cancer Using Calcium Levofolinate, Irinotecan, and Oxaliplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Interstitial lung disease

Recruiting

Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Follicular lymphoma

Recruiting

Study on Radiotherapy Alone or with Obinutuzumab for Patients with Early Stage Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Post-acute COVID-19 syndrome

Recruiting

Study on Anakinra for Patients with Long COVID and Ongoing Respiratory Symptoms

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Breast cancer metastatic

Recruiting

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Type IIa hyperlipidaemia

Recruiting

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Small cell lung cancer extensive stage

Recruiting

Study on Durvalumab with Carboplatin or Cisplatin and Etoposide for First-Line Treatment in Patients with Extensive Stage Extrapulmonary Small Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Systemic lupus erythematosus

Recruiting

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Modena

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical trials exploring treatments for pulmonary fibrosis and severe asthma, evaluating novel therapies aimed at improving lung function and patient outcomes.

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
  • High-Risk Asthma

Research focuses on evaluating forced vital capacity changes and reducing asthma exacerbations.

02 Autoimmune Conditions

Groundbreaking studies examining treatments for systemic sclerosis and related autoimmune disorders, with emphasis on innovative biological therapies.

  • Diffuse Cutaneous Systemic Sclerosis
  • Systemic Autoimmune Rheumatic Diseases
  • Interstitial Lung Diseases

Studies aim to improve skin sclerosis and manage associated complications.

03 Oncology Research

Advanced trials investigating treatments for various cancers, including gastric cancer and hematological malignancies.

  • HER2-positive Gastric Cancer
  • Follicular Lymphoma
  • Metastatic Renal Cell Carcinoma

Focus on immunotherapy combinations and targeted treatments for better patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.